Explore small cap ideas before they hit the headlines.
Explore small cap ideas before they hit the headlines.
The last one filled a little below the ask: 2.5382
I've slapped the ask twice today.....trying to help.
I agree with you iamadog. I'm not buying more due to being in way too deep on this one, but with the knowledge that I know what I've got here. I'm over a couple of million shares and will hold for multiple dollars before I start shaving some off at a time. I'm not a trader, I invest. I respect Melvin, and I intend to hold most, or at least half, of my stack for a lot of years.
I made a small one and it went below, 0.0325.
Well, that is one reason why Elon bought the thing. So he cancel anyone who doesn't agree with his stance on things. Sounds like all the other retribution that has been going on....cancel culture on steroids.
I always feel better after a little wine. ![]()
I have not seen any of this "Investors are discussing the potential for a suitor or M&A activity." I do understand that all investors look to that as a plus and an exit option. I don't believe that will be on the horizon here for a few years or more. I'm sure other companies will want to own Veemost, but it is Melvin's baby, and I'm convinced HE will not even consider an offer until his baby grows up. It has too much potential to let it go before it grows up.....let it mature like a fine wine. In the meantime, you or I can sell whenever it suits us. I personally want to see a 100x before I consider dumping much of my stack. I've got much of mine sitting in 7 or 8 GTC orders ranging from $.99 up to $9.99. ....to each, his own.
I've got a couple milly and NONE of that will go anywhere under $1. Most of it will hold for much higher valuations.
Good post OS! I like it. I live in Columbus, so if I learn anything, I'll surely post it here.
I've been here steadily for over 3 years. I haven't blamed JK for anything. ?? No explanation needed; end of discussion.
I'm not sure who that would be. You're the only one who really denigrates our CEO and company.
I totally agree with you and with SDCRBS. That BS is really old and very evident of a lack of integrity in and of itself.
I'm sure we could find a thousand times while filling the Presidential space that "Trump declared the U.S. WILL" and it didn't happen. An honest person would call them lies. So don't count on Lloyd's demise quite yet.
Same here. Been building my stack since February 2023.
Thank you for all your work, Troubles1. Good pictures. Thanks for sharing.
Why would anyone with any serious number of shares sell ALL of their shares at once? ......given that everyone's financial situation is different.
I slapped the 198 ask a while ago with a small order, and it went at 187.......game playing.
I have desired to iggy this arss many time over the years.....I think I'm there .... C is the only credible 280! unbelievable.😵
Yep, I'm waiting on $4000 to clear right now. I can buy stocks, not OTC, options, etc. Monday it will clear. It always irritates me.
I love your detailed, well-thought-out, factual posts, SDCRBS! I'm filing most of them. Keep them coming. As to that other post, I believe that Gates has no more integrity than Melvin, and I have great respect for Melvin. But then that one was someone's opinion, for what it's worth; everyone has one, just like certain other body parts.
I definitely remember a discussion about German medical area. However, I could not find anything in my files.
Yes, and he will destroy the rest of our democracy along with it, in order to become a putin. The FDA does certainly need cleaned up, however.
Thanks, Brodey. More progress. Obviously, things are moving forward.
Thanks, Troubles! That answers a lot of our questions. Sounds like the pig became a bullet.
Wow, you are a busy boy today, your first day, as you have posted 16 times on this board.... today! I did really like this fact that you stated: "cannot take a world Trump says to be true or he will honor his words." It's not written well, but I do understand what you are trying to state: he only lies...... when his lips move.
Mine aren't in those totals, but I have 447,000 HGEN and 128,000 IPIX. I haven't sold or turned in any shares. I see we have a brand-new account today who seems to have a lot of pent-up anger, judging from the large number of posts that seem to be mostly talking to himself. I do agree with a little of what was said, like: "....the FDA is now like the SEC..cannot be trusted to protect the health of the public and totally corrupt. as the FDA is controlled by big pharma..."
I like it. Thanks. Those are nice numbers, but do we have any idea, IF or what percentage of that might flow our way? Or is that possible % combined with a fee from Ohio for our services that let them more efficiently buy, track/manage, etc. their licenses? I don't think we can estimate anything until Melvin tells us.
A spectacular squeeze!?
Great post, SDCRBS! Thanks for the reminders and details you have been posting. Since I'm from Ohio (and since Melvin was living in Akron), I asked Gemini for some more detail/clarification and confirmation on the Ohio contracts. ---->
Based on public records from the Ohio Department of Administrative Services (DAS) and OhioBuys, here is the current status and specific details regarding Veemost Technologies Inc.’s contracts with the State of Ohio.
1. Key Active Contract: IBM Software & Services
A significant public filing from late 2025 confirms that Veemost Technologies Inc. has established a formal agreement with the State of Ohio for IBM solutions.
Scope: This agreement allows the State of Ohio and its various agencies to purchase IBM software licenses through Veemost.
Terms: The contract was established for a period of one year (expiring in late 2026), designed to eliminate the need for individual competitive bidding for each purchase.
Eligibility: It is a statewide agreement, meaning any Ohio state agency, board, or commission can procure licenses directly under these pre-negotiated terms.
2. VeeBids Platform Integration
The contract mentioned above is managed through Veemost’s proprietary VeeBids platform. According to company disclosures to the OTC Markets:
VeeBids is used to "streamline the government procurement process."
It serves as the interface for state and local entities in Ohio to source critical technology solutions while maintaining compliance with state procurement rules.
3. E-Rate & Education Sector Contracts
Veemost has a strong presence in the Ohio E-Rate program (the federal program for schools and libraries).
Recent Wins: In March 2025, Veemost announced winning nine (9) E-Rate bids specifically for technology infrastructure and cybersecurity solutions for Ohio schools.
Funding Category: Most of these fall under "Category Two" funding, which covers internal connections and managed broadband services.
4. How to View Full Documents in OhioBuys
While the high-level details are public, the state-specific contract number (typically starting with CTR or STS) and the line-item pricing can be found in the OhioBuys Public Catalog by following these steps:
Visit the Portal: OhioBuys Public Catalog.
Search Supplier: Type "Veemost Technologies" into the "Supplier" field.
Find the CTR Number: Look for the most recent entry related to "IT Software" or "IBM Licenses."
Note: If the specific document is not visible, you can submit a Public Records Request directly through the "S.04" portal in OhioBuys for any contract involving "Veemost Technologies Inc."
Summary of Vendor Partnerships
Through their state-level standing, Veemost is authorized to provide products from the following partners to Ohio government entities:
IBM (Primary Software Contract)
Cisco (Networking and Security)
Lenovo & Nutanix (Infrastructure)
Vertiv (Power and Cooling)
Good info, Oldstocks! Thanks for sharing all your hard work.
Interesting find from MOL info. Of course, we know they have contracts and investment with Delfin but check this confirmation: The picture captioned "Conceptual drawing of completed FLNG" is the EXACT picture from the Delfin corporate presentation from March, 2025.
Double WOW! LOL!
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
SEATTLE, Dec. 11, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy ("DMD").
RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. Upon approval of a qualifying marketing application, drugs with RPD designation may be eligible for a Priority Review Voucher ("PRV"), which can be used to obtain priority review for a future application or may be sold or transferred to another sponsor. In the last 18–24 months, disclosed PRV sales have ranged from $100–$160 million.
"This designation is an important regulatory milestone for Atossa, and we believe a strong validation of the science supporting the potential of (Z)-Endoxifen as a treatment for Duchenne Muscular Dystrophy," said Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer. "DMD is one of the most devastating childhood diseases. Families urgently need better options beyond steroids and gene-targeted approaches. While oncology remains our core focus, this milestone highlights (Z)-Endoxifen's potential as a platform therapy in both cancer and rare diseases, opening the door to potential non-dilutive value creation through the Rare Pediatric Disease program."
"RPD designation provides a regulatory framework and an enhanced level of interaction with the FDA as we define the clinical development path in DMD," said Janet Rea, MSPH, Senior Vice President of Research and Development at Atossa. "We are very encouraged by emerging preclinical data and by (Z)-Endoxifen's potential to be a differentiated mechanism as a potent SERM/D, and look forward to our planned advancement of this program to the clinic for boys living with DMD. Unlike more recent therapeutic approaches, (Z)-Endoxifen does not target specific exon defects, thus potentially offering a broader and more accessible treatment approach for this patient population. Having previously secured IND clearance for what is now the DMD treatment, Exondys 51® (eteplirsen), I am excited to further Atossa's DMD (Z)-Endoxifen program."
About Rare Pediatric Disease Designation
The FDA's Rare Pediatric Disease designation is reserved for serious or life-threatening diseases that primarily affect individuals from birth to 18 years old and that meet the definition of a rare disease or condition within the meaning of Section 526 of the Federal Food, Drug & Cosmetic Act ("FD&C Act").
Currently, the FDA may not award any new rare pediatric disease PRVs unless the application is (i) for a drug that is designated as a drug for a rare pediatric disease not later than December 20, 2024, and (ii) is approved under the program not later than September 30, 2026. The House has passed the Mikaela Naylon "Give Kids a Chance Act" to extend voucher-award authority to 2029, with retroactive effect, and the bill is now pending Senate action.
Assuming the program is renewed, drugs granted RPD designation may be eligible for a PRV upon FDA approval of a qualifying New Drug Application or Biologics License Application, provided it meets all statutory criteria under Section 529(a)(4) of the FD&C Act. A PRV may be used by the sponsor or sold or transferred to another company.
About Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy is a rare, progressive, X-linked neuromuscular disorder caused by mutations in the dystrophin gene. Symptoms typically emerge in early childhood and include progressive muscle weakness, loss of ambulation, respiratory compromise, and cardiomyopathy. DMD is uniformly fatal, often in early adulthood, and despite recent therapeutic advances, there remains a substantial unmet medical need for safe, effective, and accessible treatments.
About (Z)-Endoxifen
(Z)-Endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms of interest. Atossa is evaluating its potential applications in oncology and rare diseases. The Company's proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa's (Z)-Endoxifen is not approved for any indication.
Atossa's (Z)-Endoxifen program is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company's lead product candidate, (Z)-Endoxifen, is currently in development across several clinical settings. More information is available at https://atossatherapeutics.com.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of applicable securities laws, including but not limited to, our expectations regarding the Company's development and regulatory strategy and related milestones, the potential indications that the Company may pursue for (Z)-Endoxifen, the potential for (Z)-Endoxifen to receive regulatory approval and the timing thereof, the potential extension of the RPD Priority Review Voucher program and the Company's potential eligibility for and value of a future Priority Review Voucher, and the potential market and growth opportunities for the Company. Words such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "believe," "design," "predict," "future," or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with: our ability to successfully execute our strategy to shorten our clinical development timelines and pursue a metastatic breast cancer indication, DMD indication or other indications for our lead program, (Z)-Endoxifen; expected timing, completion and results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; our ability to receive a Priority Review Voucher for (Z)-Endoxifen, if approved, which is subject to, among other factors, the U.S. federal government's extension of the RPD PRV program and such extension being effective retroactively; our ability to regain and maintain compliance with Nasdaq listing requirements; our ability to establish and maintain intellectual property rights covering our products; the impact of general macroeconomic conditions on our business; our ability to raise capital; and other risks and uncertainties detailed from time to time in Atossa's filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
The market value of a Priority Review Voucher is variable and subject to a number of factors beyond our control and reported past PRV sale amounts are not necessarily indicative of PRV sale amounts in the future.
Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.
SOURCE Atossa Therapeutics Inc
Thanks Pic! Nice article.
Thanks Pic! Nice article.
Thank you SO much for sharing your DD and explanations. It is great being on a board with a group this good! Melvin will get there.
Great research OS and TJG! THANKS for reminding us, for pulling it all together, and for solving the riddle! Most of all, we know that is your DD and you didn't have share, but you always do.
No need to increase the shares through a split; an increase in authorized shares would be a good move. That would be necessary if they want treasury cash through secondary offerings......or to use shares as cash.